GH RESEARCH PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.33 USD | +4.96% |
|
+4.71% | +129.83% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 661M |
|---|---|---|---|---|---|
| Net income 2024 * | -42M | Net income 2025 * | -72M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 237M | Net cash position 2025 * | 265M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-16.1
x | P/E ratio 2025 * |
-10.8
x | Employees | 49 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.61% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +4.96% | ||
| 1 week | +4.63% | ||
| Current month | +21.62% | ||
| 1 month | +13.74% | ||
| 3 months | +79.17% | ||
| 6 months | +92.91% | ||
| Current year | +129.83% |
1 week
12.09
13.90
1 month
10.3013.90
Current year
5.1213.90
1 year
5.0514.64
3 years
5.0530.43
5 years
5.0530.43
10 years
5.0530.43
| Managers | Title | Age | Since |
|---|---|---|---|
Magnus Halle
FOU | Founder | 27 | 17-12-31 |
Theis Terwey
CEO | Chief Executive Officer | 48 | 17-12-31 |
Julie Ryan
DFI | Director of Finance/CFO | 38 | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Duncan Moore
BRD | Director/Board Member | 65 | 21-09-23 |
| Founder | 55 | 17-12-31 | |
Michael Forer
BRD | Director/Board Member | 58 | 20-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 13.33 | +4.96% | 43,485 |
| 24-05-22 | 12.7 | +2.75% | 63,785 |
| 24-05-21 | 12.36 | -6.93% | 81,532 |
| 24-05-20 | 13.28 | +5.40% | 43,934 |
| 24-05-17 | 12.6 | -1.02% | 43,846 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotes
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.7
USD
Average target price
32
USD
Spread / Average Target
+151.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +129.83% | 661M | |
| +10.79% | 115B | |
| +11.65% | 106B | |
| -6.20% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.41% | 17.56B | |
| -40.50% | 17.32B | |
| +6.64% | 14.03B | |
| +31.84% | 12.13B |
- Stock Market
- Equities
- GHRS Stock
